ESMO 2023 BioNTech Data

BNT221: A Personalized, Autologous Non-Engineered Neoantigen-Specific T Cell Product • A systematic, highly reproducible approach to expand neoantigen-specific T cells Fully personalized product • Drug product contains polyclonal neoantigen CD4+ and CD8+ T cell responses. NEO-STIM® • Potential to circumvent antigen escape PBMC starting material • Material obtained from leukapheresis Clinical opportunity MMX • Broad clinical opportunity due to targeting of personalized mutations RECON ANFORMATICS 00000 Tumor Sample DNA & RNA Bioinformatics & Processing Sequencing Personalized Peptide Manufacturing PBMC peripheral blood mononuclear cell. NEO STIM Prime Activate → Expand T cell Epitopes Leukapheresis APCs & T cells BNT221 Personalized Neoantigen T Cell Therapy BIONTECH

View entire presentation